Powered by

OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020; -- 30% overall response rate (ORR) and 6% complete response (CR) rate achieved --

Nov 09, 2020 - PR Newswire

PR Newswire

 OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced new positive interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial evaluating TAVO™ (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), in combination with KEYTRUDA® (pembrolizumab) in rigorously defined anti-PD1 checkpoint resistant metastatic melanoma patients.

TAVO + KEYTRUDA led to a 30% ORR in the first 54 out of 100 planned patie...